Edgewise Therapeutics Stock Forum

$Edgewise Therapeutics (EWTX.US)$
Edgewise Therapeutics Announces Positive Topline Results from the CANYON Phase 2 Trial of Sevasemten in Individuals with Becker Muscular Dystrophy (Becker)
– Trial met primary endpoint of reduction in circulating levels of creatine kinase (CK), a biomarker associated with skeletal muscle damage, in the largest Becker interventional trial to date –
– On the key secondary endpoint, sevasemten-treated patients showed stabilization of North Star Ambulatory Assess...

🎯 Ph 2 readouts in Q2 2024...
$Iovance Biotherapeutics (IOVA.US)$  Phase 2
$Supernus Pharmaceuticals (SUPN.US)$  Phase 2a
$BRANDES INTERNATIONAL ETF (BINV.US)$  Phase 2a
$MorphoSys (MOR.US)$  Phase 2
$Nuvation Bio (NUVB.US)$  Phase 2
$ALX Oncology (ALXO.US)$  Phase 2
$BioXcel Therapeutics (BTAI.US)$  Phase 2
$Purple Biotech (PPBT.US)$  Phase 2
$Arcus Biosciences (RCUS.US)$  Phase 2
$Medicenna Therapeutics (MDNAF.US)$  Phase 2b
$Affimed NV (AFMD.US)$  Phase 2
$Barinthus Biotherapeutics (BRNS.US)$  Phase 2b...

» Holdings: 75
» Holdings in Top 20: 70.21%
» Qtr over Qtr Change**: +21.81%
Top Holdings:
$Ascendis Pharma A/S (ASND.US)$
$Vaxcyte (PCVX.US)$
$Legend Biotech (LEGN.US)$
$Janux Therapeutics (JANX.US)$
$Aerovate (AVTE.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Evolent Health (EVH.US)$
$NewAmsterdam Pharma (NAMS.US)$
$RxSight (RXST.US)$
$TYRA BIOSCIENCES, INC. (TYRA.US)$
$Edgewise Therapeutics (EWTX.US)$
$4D Molecular Therapeutics (FDMT.US)$
$Biogen (BIIB.US)$
$PepGen (PEPG.US)$
...

» Holdings: 87
» Holdings in Top 20: 86.71%
» Qtr over Qtr Change**: -9.29%
Top Holdings:
$Incyte (INCY.US)$
$BeiGene (BGNE.US)$
$ACADIA Pharmaceuticals (ACAD.US)$
$Madrigal Pharmaceuticals (MDGL.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Revolution Medicines (RVMD.US)$
$Kymera Therapeutics (KYMR.US)$
$AbCellera Biologics (ABCL.US)$
$Bicycle Therapeutics (BCYC.US)$
$Edgewise Therapeutics (EWTX.US)$
$Immunocore (IMCR.US)$
$Kodiak Sciences (KOD.US)$
$Roivant Sciences (ROIV.US)$
...

$Edgewise Therapeutics (EWTX.US)$
NEWS
Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker)
Positive two-year topline results from the ARCH trial show stabilization of NSAA scores with sevasemten treatment in adults with Becker Muscular Dystrophy.
Significant decreases in muscle damage biomarkers CK and TNNI2 were observed in participants treated with sevasemten.
Sevasemten was...

$Edgewise Therapeutics (EWTX.US)$ LOAD THE BOAT not financial advice

$Edgewise Therapeutics (EWTX.US)$ I think I saw somewhere it was on October 26. but I can't find the news on google anymore